NO20073559L - Nanopartiklulaere tacrolimus-formuleringer - Google Patents
Nanopartiklulaere tacrolimus-formuleringerInfo
- Publication number
- NO20073559L NO20073559L NO20073559A NO20073559A NO20073559L NO 20073559 L NO20073559 L NO 20073559L NO 20073559 A NO20073559 A NO 20073559A NO 20073559 A NO20073559 A NO 20073559A NO 20073559 L NO20073559 L NO 20073559L
- Authority
- NO
- Norway
- Prior art keywords
- nanoparticulate tacrolimus
- tacrolimus formulations
- nanoparticulate
- formulations
- tacrolimus
- Prior art date
Links
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 229960001967 tacrolimus Drugs 0.000 title abstract 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title 1
- 239000002245 particle Substances 0.000 abstract 2
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63681704P | 2004-12-15 | 2004-12-15 | |
| US73186905P | 2005-11-01 | 2005-11-01 | |
| PCT/US2005/045540 WO2006066063A1 (fr) | 2004-12-15 | 2005-12-15 | Formulations renfermant des nanoparticules de tacrolimus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20073559L true NO20073559L (no) | 2007-08-29 |
Family
ID=36190417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20073559A NO20073559L (no) | 2004-12-15 | 2007-07-09 | Nanopartiklulaere tacrolimus-formuleringer |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20060159766A1 (fr) |
| EP (1) | EP1835889A1 (fr) |
| JP (1) | JP2008524239A (fr) |
| KR (1) | KR20070116581A (fr) |
| AU (1) | AU2005316473B2 (fr) |
| BR (1) | BRPI0519088A2 (fr) |
| CA (1) | CA2590675A1 (fr) |
| EA (1) | EA013741B1 (fr) |
| IL (1) | IL183945A0 (fr) |
| MX (1) | MX2007007342A (fr) |
| NO (1) | NO20073559L (fr) |
| SG (1) | SG161203A1 (fr) |
| WO (1) | WO2006066063A1 (fr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2812185B1 (fr) | 2000-07-25 | 2003-02-28 | Spine Next Sa | Piece de liaison semi-rigide pour la stabilisation du rachis |
| US20060169199A1 (en) * | 2003-03-31 | 2006-08-03 | Vilmos Keri | Crystallization and purification of macrolides |
| BRPI0414000B8 (pt) | 2003-08-29 | 2021-05-25 | Lifecycle Pharma As | composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica |
| CN1859909B (zh) * | 2003-08-29 | 2011-04-06 | 生命周期药物公司 | 含有他克莫司的固态分散体 |
| CN101175481A (zh) * | 2005-03-17 | 2008-05-07 | 伊兰制药国际有限公司 | 纳米颗粒免疫抑制化合物的可注射的组合物 |
| EP2343053A1 (fr) * | 2006-05-30 | 2011-07-13 | Elan Pharma International Limited | Compositions de posaconazole nanoparticulaire |
| EP2049084A2 (fr) * | 2006-07-10 | 2009-04-22 | Elan Pharma International Limited | Formulations de sorafenib nanoparticulaire |
| CA2663610C (fr) * | 2006-09-29 | 2015-11-03 | Infa S.A. | Systeme de conditionnement pour compositions pharmaceutiques et necessaire pour administration par voie intraveineuse |
| WO2008066899A2 (fr) * | 2006-11-28 | 2008-06-05 | Marinus Pharmaceuticals | Formulations de nanoparticules et procédés de préparation et d'utilisation de celles-ci |
| US20080138405A1 (en) * | 2006-12-06 | 2008-06-12 | Raheja Praveen | Sirolimus nanodispersion |
| CA3027598C (fr) | 2007-01-10 | 2020-07-21 | Board Of Regents The University Of Texas System | Administration amelioree de compositions medicamenteuses immunosuppressives par voie pulmonaire |
| NZ579811A (en) * | 2007-03-29 | 2012-02-24 | Panacea Biotec Ltd | Modified dosage forms of tacrolimus |
| PL2167033T4 (pl) | 2007-05-30 | 2018-08-31 | Veloxis Pharmaceuticals A/S | Podawana raz dziennie doustna postać dawkowania zawierająca takrolimus |
| US12083103B2 (en) | 2007-05-30 | 2024-09-10 | Veloxis Pharmaceuticals, Inc. | Tacrolimus for improved treatment of transplant patients |
| WO2009029543A1 (fr) | 2007-08-24 | 2009-03-05 | Aegis Therapeutics, Llc | Formulations à libération contrôlée |
| PL2200588T3 (pl) | 2007-09-25 | 2019-09-30 | Solubest Ltd. | Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania |
| WO2009073215A1 (fr) * | 2007-12-06 | 2009-06-11 | Bend Research, Inc. | Compositions pharmaceutiques comprenant des nanoparticules et une matière de remise en suspension |
| CL2008000374A1 (es) | 2008-02-05 | 2008-04-04 | Igloo Zone Chile S A | Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve |
| EP2268265A2 (fr) * | 2008-03-21 | 2011-01-05 | Elan Pharma International Limited | Compositions pour la délivrance d imatinib spécifique du site et procédés d utilisation |
| US12403095B2 (en) | 2008-05-30 | 2025-09-02 | Veloxis Pharmaceuticals, Inc. | Stabilized tacrolimus composition |
| RU2535017C2 (ru) * | 2008-09-19 | 2014-12-10 | Активус Фарма Ко., Лтд. | Композитный порошок из органического вещества для применения в медицине, способ его получения и его суспензия |
| EP2365802B1 (fr) | 2008-11-11 | 2017-08-02 | The Board of Regents,The University of Texas System | Microcapsules de rapamycine et l'usage pour le traitement du cancer |
| CA2757979A1 (fr) * | 2009-04-09 | 2010-10-14 | Alkermes Pharma Ireland Limited | Compositions de clozapine a liberation controlee |
| EP2421525B1 (fr) | 2009-04-24 | 2017-06-07 | Iceutica Pty Ltd. | Formulation de diclofénac |
| EP3167875A1 (fr) * | 2009-05-27 | 2017-05-17 | Alkermes Pharma Ireland Limited | Réduction d'agrégation de type paillettes dans des compositions de meloxicam nanoparticulaire |
| AU2010261342A1 (en) * | 2009-06-19 | 2012-01-19 | Sun Pharma Advanced Research Company Ltd., | Nanodispersion of a drug and process for its preparation |
| US20170079962A1 (en) | 2009-11-11 | 2017-03-23 | Rapamycin Holdings, Llc | Oral Rapamycin Preparation and Use for Stomatitus |
| WO2011100975A2 (fr) * | 2010-02-17 | 2011-08-25 | Lifecycle Pharma A/S | Composition à base de tacrolimus stabilisée |
| MA34586B1 (fr) * | 2010-08-25 | 2013-10-02 | Medis Lab | Particules cristallines de tacrolimus micronise a surface modifiee et compositions pharmaceutiques associees |
| CN103501812A (zh) | 2011-04-29 | 2014-01-08 | 西莱克塔生物科技公司 | 用于过敏症治疗的致耐受性合成纳米载体 |
| JP6382187B2 (ja) | 2012-06-21 | 2018-08-29 | フォスフォレックス，インコーポレーテッド | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
| MX2015004973A (es) * | 2012-10-18 | 2015-07-17 | Abbvie Inc | Formulaciones de compuestos derivados de pirimidindiona. |
| KR20150123838A (ko) * | 2013-03-04 | 2015-11-04 | 브이티브이 테라퓨틱스 엘엘씨 | 안정한 글루코키나제 활성화제 조성물 |
| US20160030401A1 (en) | 2013-03-13 | 2016-02-04 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors for prevention of intestinal polyp growth and cancer |
| CA2910584A1 (fr) | 2013-05-03 | 2014-11-06 | Selecta Biosciences, Inc. | Utilisation d'immunosuppresseurs attaches a des nanoporteurs synthetiques pour ameliorer les niveaux des lymphocytes t regulateurs cd4+ |
| WO2015071841A1 (fr) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes de dabigatran et ses dérivés, procédé de préparation de ceux-ci et compositions pharmaceutiques contenant ceux-ci |
| CA3206208A1 (fr) | 2013-12-31 | 2015-07-09 | Rapamycin Holdings, Llc | Preparations orales de nanoparticules de rapamycine, et utilisation |
| EP3592389B1 (fr) | 2017-03-11 | 2025-05-07 | Cartesian Therapeutics, Inc. | Procédés et compositions associés à un traitement combiné avec anti-inflammatoires et nanovecteurs synthétiques comprenant un immunosuppresseur |
| CA3063417C (fr) | 2018-12-04 | 2023-01-03 | Leon-Nanodrugs Gmbh | Nanoparticules comprenant du tacrolimus |
| TWI764159B (zh) | 2019-05-31 | 2022-05-11 | 財團法人醫藥工業技術發展中心 | 口服組合物、製造方法及其用途 |
| EP4014963A1 (fr) | 2020-12-16 | 2022-06-22 | Medincell | Composition pharmaceutique |
| WO2024117136A1 (fr) * | 2022-11-29 | 2024-06-06 | 学校法人自治医科大学 | Procédé de quantification d'analyte contenant de l'acide mycophénolique et au moins un autre immunosuppresseur dans un échantillon de sang cible |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4894366A (en) * | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
| US4826689A (en) * | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
| US4783484A (en) * | 1984-10-05 | 1988-11-08 | University Of Rochester | Particulate composition and use thereof as antimicrobial agent |
| AU642066B2 (en) * | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
| US5552160A (en) * | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5194378A (en) * | 1991-01-28 | 1993-03-16 | Merck & Co., Inc. | Process for producing fk-506 |
| JPH06511481A (ja) * | 1991-07-05 | 1994-12-22 | ユニバーシティ オブ ロチェスター | 気泡を取り込む超微小非凝集多孔質粒子 |
| NZ248813A (en) * | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
| US5349957A (en) * | 1992-12-02 | 1994-09-27 | Sterling Winthrop Inc. | Preparation and magnetic properties of very small magnetite-dextran particles |
| US5346702A (en) * | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
| US5298262A (en) * | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
| US5302401A (en) * | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
| US5340564A (en) * | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
| US5336507A (en) * | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
| US5429824A (en) * | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
| US5352459A (en) * | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
| US5326552A (en) * | 1992-12-17 | 1994-07-05 | Sterling Winthrop Inc. | Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants |
| US5401492A (en) * | 1992-12-17 | 1995-03-28 | Sterling Winthrop, Inc. | Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents |
| US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5264610A (en) * | 1993-03-29 | 1993-11-23 | Sterling Winthrop Inc. | Iodinated aromatic propanedioates |
| US5718388A (en) * | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
| TW384224B (en) * | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
| US5525328A (en) * | 1994-06-24 | 1996-06-11 | Nanosystems L.L.C. | Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging |
| US5587143A (en) * | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5466440A (en) * | 1994-12-30 | 1995-11-14 | Eastman Kodak Company | Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays |
| US5585108A (en) * | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
| US5628981A (en) * | 1994-12-30 | 1997-05-13 | Nano Systems L.L.C. | Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents |
| US5560932A (en) * | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
| US5662883A (en) * | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
| US5665331A (en) * | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
| US5569448A (en) * | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5571536A (en) * | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5560931A (en) * | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5534270A (en) * | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5622938A (en) * | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
| US5518738A (en) * | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
| US5593657A (en) * | 1995-02-09 | 1997-01-14 | Nanosystems L.L.C. | Barium salt formulations stabilized by non-ionic and anionic stabilizers |
| US5591456A (en) * | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
| US5500204A (en) * | 1995-02-10 | 1996-03-19 | Eastman Kodak Company | Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging |
| US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5543133A (en) * | 1995-02-14 | 1996-08-06 | Nanosystems L.L.C. | Process of preparing x-ray contrast compositions containing nanoparticles |
| US5580579A (en) * | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| US5747001A (en) * | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
| US5565188A (en) * | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
| US5718919A (en) * | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
| EP0810853B1 (fr) * | 1995-02-24 | 2004-08-25 | Elan Pharma International Limited | Aerosols contenant des dispersions de nanoparticules |
| US5573749A (en) * | 1995-03-09 | 1996-11-12 | Nano Systems L.L.C. | Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging |
| US5472683A (en) * | 1995-03-09 | 1995-12-05 | Eastman Kodak Company | Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging |
| US5643552A (en) * | 1995-03-09 | 1997-07-01 | Nanosystems L.L.C. | Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging |
| US5521218A (en) * | 1995-05-15 | 1996-05-28 | Nanosystems L.L.C. | Nanoparticulate iodipamide derivatives for use as x-ray contrast agents |
| US5573750A (en) * | 1995-05-22 | 1996-11-12 | Nanosystems L.L.C. | Diagnostic imaging x-ray contrast agents |
| US5834025A (en) * | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
| WO1997014407A1 (fr) * | 1995-10-17 | 1997-04-24 | Research Triangle Pharmaceuticals | Administration de medicaments insolubles |
| US6458811B1 (en) * | 1996-03-26 | 2002-10-01 | Eli Lilly And Company | Benzothiophenes formulations containing same and methods |
| US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| WO1998035666A1 (fr) * | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Preparation de pastilles de naproxene nanoparticulaire |
| US6153225A (en) * | 1998-08-13 | 2000-11-28 | Elan Pharma International Limited | Injectable formulations of nanoparticulate naproxen |
| US6165506A (en) * | 1998-09-04 | 2000-12-26 | Elan Pharma International Ltd. | Solid dose form of nanoparticulate naproxen |
| US8293277B2 (en) * | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
| HU230454B1 (hu) * | 1998-11-02 | 2016-07-28 | Alkermes Pharma Ireland Limited | Metilfenidátot tartalmazó módosított felszabadulású sokszemcsés készítmény |
| US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
| US6375986B1 (en) * | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
| US6428814B1 (en) * | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
| US6270806B1 (en) * | 1999-03-03 | 2001-08-07 | Elan Pharma International Limited | Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions |
| US6267989B1 (en) * | 1999-03-08 | 2001-07-31 | Klan Pharma International Ltd. | Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions |
| JP4156807B2 (ja) * | 1999-06-01 | 2008-09-24 | エラン ファーマ インターナショナル，リミティド | 小型ミル及びその方法 |
| US6656504B1 (en) * | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
| US20040026546A1 (en) * | 2000-04-26 | 2004-02-12 | Czekai David A | Apparatus for sanitary wet milling |
| US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| US20030224058A1 (en) * | 2002-05-24 | 2003-12-04 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
| US6884436B2 (en) * | 2000-12-22 | 2005-04-26 | Baxter International Inc. | Method for preparing submicron particle suspensions |
| ATE319432T1 (de) * | 2000-12-22 | 2006-03-15 | Baxter Int | Verfahren zur herstellung von submikropartikel- suspensionen pharmazeutischer substanzen |
| DE60227802D1 (de) * | 2001-06-05 | 2008-09-04 | Elan Pharma Int Ltd | Mahlvorrichtung und verfahren zu deren betrieb |
| DE60222160T2 (de) * | 2001-10-12 | 2008-06-12 | Elan Pharma International Ltd., Athlone | Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung |
| US6780324B2 (en) * | 2002-03-18 | 2004-08-24 | Labopharm, Inc. | Preparation of sterile stabilized nanodispersions |
| US7101576B2 (en) * | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
| JP2005531606A (ja) * | 2002-06-10 | 2005-10-20 | エラン ファーマ インターナショナル，リミティド | ナノ粒子ステロール製剤およびステロールの組合せ |
| EP1511467A1 (fr) * | 2002-06-10 | 2005-03-09 | Elan Pharma International Limited | Formulation de polycosanol nanoparticulaires et nouvelles combinaisons de polycosanol |
| EP2283864A1 (fr) * | 2002-07-16 | 2011-02-16 | Elan Pharma International Ltd. | Composition liquide contenant des nanoparticules stabilisées d'une substance active |
| CA2500908A1 (fr) * | 2002-10-04 | 2004-04-22 | Elan Pharma International Limited | Irradiation gamma d'agents actifs nanoparticulaires solides |
| WO2004058216A2 (fr) * | 2002-12-17 | 2004-07-15 | Elan Pharma International Ltd. | Broyage de quantites de composes candidats nanoparticulaires de l'ordre du microgramme |
| MXPA05012467A (es) * | 2003-05-19 | 2006-02-22 | Baxter Int | Particulas solidas que comprenden un anticonvulsivo o un inmunosupresor revestido con uno o mas modificadores de superficie. |
| CN101175481A (zh) * | 2005-03-17 | 2008-05-07 | 伊兰制药国际有限公司 | 纳米颗粒免疫抑制化合物的可注射的组合物 |
-
2005
- 2005-12-15 JP JP2007546924A patent/JP2008524239A/ja active Pending
- 2005-12-15 KR KR1020077015992A patent/KR20070116581A/ko not_active Ceased
- 2005-12-15 EA EA200701274A patent/EA013741B1/ru not_active IP Right Cessation
- 2005-12-15 BR BRPI0519088-6A patent/BRPI0519088A2/pt not_active IP Right Cessation
- 2005-12-15 MX MX2007007342A patent/MX2007007342A/es not_active Application Discontinuation
- 2005-12-15 EP EP05854300A patent/EP1835889A1/fr not_active Withdrawn
- 2005-12-15 WO PCT/US2005/045540 patent/WO2006066063A1/fr not_active Ceased
- 2005-12-15 CA CA002590675A patent/CA2590675A1/fr not_active Abandoned
- 2005-12-15 SG SG201001728-3A patent/SG161203A1/en unknown
- 2005-12-15 US US11/300,592 patent/US20060159766A1/en not_active Abandoned
- 2005-12-15 AU AU2005316473A patent/AU2005316473B2/en not_active Ceased
-
2007
- 2007-06-14 IL IL183945A patent/IL183945A0/en unknown
- 2007-07-09 NO NO20073559A patent/NO20073559L/no not_active Application Discontinuation
-
2008
- 2008-02-27 US US12/071,849 patent/US20080152720A1/en not_active Abandoned
-
2009
- 2009-06-12 US US12/484,073 patent/US20090252806A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005316473A1 (en) | 2006-06-22 |
| EA200701274A1 (ru) | 2007-12-28 |
| US20080152720A1 (en) | 2008-06-26 |
| JP2008524239A (ja) | 2008-07-10 |
| WO2006066063A1 (fr) | 2006-06-22 |
| KR20070116581A (ko) | 2007-12-10 |
| AU2005316473B2 (en) | 2011-07-14 |
| CA2590675A1 (fr) | 2006-06-22 |
| EA013741B1 (ru) | 2010-06-30 |
| MX2007007342A (es) | 2007-12-11 |
| US20090252806A1 (en) | 2009-10-08 |
| BRPI0519088A2 (pt) | 2008-12-23 |
| US20060159766A1 (en) | 2006-07-20 |
| EP1835889A1 (fr) | 2007-09-26 |
| IL183945A0 (en) | 2007-10-31 |
| SG161203A1 (en) | 2010-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20073559L (no) | Nanopartiklulaere tacrolimus-formuleringer | |
| NO20073780L (no) | Nanopartikulaere kandesartan-formuleringer | |
| DE602004021107D1 (de) | Meloxican-formulierungen in nanoteilchenform | |
| DE60325718D1 (de) | Nystatin-nanopartikelzusammensetzungen | |
| DE60235411D1 (de) | Sterile gefilterte nanoteilchen-formulierungen von budesonid mit tyloxapol als oberflächenstabilisator | |
| WO2007064912A3 (fr) | Nouvelles compositions de mometasone et procedes de fabrication et utilisation de celles-ci | |
| EA200702638A1 (ru) | Стабильная композиция (рецептура) с наночастицами ацетаминофена | |
| NO20073334L (no) | Nanopartikulaert benzotiofenformuleringer | |
| EA200701997A1 (ru) | Композиция из наночастиц бисфосфоната | |
| DE602004018150D1 (de) | Neue metaxalon-zusammensetzungen | |
| DK1471887T3 (da) | Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel | |
| AR063940A1 (es) | Formulaciones de posaconazol nanoparticulado | |
| WO2005013937A3 (fr) | Nouvelles compositions de base libre de sildenafil | |
| ATE343376T1 (de) | Nanopartikelzusammensetzungen von angiogeneseinhibitoren | |
| WO2005044234A3 (fr) | Compositions nanoparticulaires comprenant un peptide comme stabilisant de surface | |
| WO2010138539A3 (fr) | Réduction de l'agrégation à l'origine de paillettes dans des compositions à base d'un principe actif nanoparticulaire | |
| MX2010009866A (es) | Composiciones de inhibidores de angiogenesis en nanoparticulas. | |
| NO20080403L (no) | Nanopartikulaere megestrolformuleringer | |
| WO2008073982A3 (fr) | Composés de 5,6-dihydro-1h-pyridine-2-one | |
| EA201070378A1 (ru) | Фармацевтические составы орлистата | |
| TW200636025A (en) | Light stabilizer emulsion composition | |
| EA200702595A1 (ru) | Композиции контролируемого высвобождения в форме наночастиц, содержащие ингибитор агрегации тромбоцитов | |
| WO2006138421A3 (fr) | Formulations d'azelnidipine nanoparticulaire | |
| ATE446742T1 (de) | Nanopartikuläre ebastinformulierungen | |
| EA200800092A1 (ru) | Композиции в виде наночастиц и с контролируемым высвобождением, включающие арил-гетероциклические соединения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |